Study Title
OZM-075: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers
Protocol ID
OZM-075 (Hypermutant Cancer)
Condition/s
Refractory or Recurrent Hypermutated Malignancies
Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
Diagnosis Stage
Relapse/ refractory
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
The Hospital for Sick Children
The Hospital for Sick Children
Collaborators
Bristol-Myers Squibb
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Pilot
Age Eligibility
12 months to 25 years
International registry ID's
NCT02992964
| Study Title | OZM-075: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers |
|---|---|
| Protocol ID | OZM-075 (Hypermutant Cancer) |
| Disease (Sub Disease) | Refractory or Recurrent Hypermutated Malignancies Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients |
| Diagnosis Stage | Relapse/ refractory |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ The Hospital for Sick Children |
| Collaborators | Bristol-Myers Squibb |
| Links | https://clinicaltrials.gov/ct2/show/study/NCT02992964 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 06/12/2019 |
| Study Type | Treatment |
| Phase | Pilot |
| Age Eligibility | 12 months to 25 years |
| International registry ID's | NCT02992964 |